BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $22 and keeps a Neutral rating on the shares post the fiscal Q3 report. The main update was the positive Phase 2 results of brepocitinib in cutaneous sarcoidosis, the analyst tells investors in a research note. The firm cites a higher brepocitinib sales forecast for the target boost.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: